Arthritis & Rheumatism, Volume 62,
November 2010 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Atlanta, Georgia November 6-11, 2010.
Outcomes of Barrett's Esophagus Related to Systemic Sclerosis: A 3-Year EULAR/EUSTAR Prospective Follow-Up Study.
Wipff11, Julien, Coriat9, Romain, Masciocchi5, Michela, Caramaschi2, Paola, Derk7, Chris T., Hachulla8, Eric, Riccieri12, Valeria
Department of Dermatology, Medical University of Lublin, Lublin
Paris Descartes University, Internal Medicine Dpt, Cochin Hospital
Paris Descartes University, Rheumatology A Dpt, Cochin Hospital
Sapienza University of Rome, Medical Clinic and Therapy Department, Rome
University of Florence, Firenze, Italy
Department of Medicine, Verona University, Verona
Hopital Cochin, Paris, France
Hopitaux de Paris Cochin, Paris, France
Immunological Clinic, Mangiagalli Regina Elena Fundation, Milan
Institute of Rheumatology, Russian Academy of Medical Science, Moscow
Jefferson Medical College, Philadelphia, PA
National Scleroderma Centre, Lille Cedex, France
Paris Descartes University, Gastroenterology Dpt, Cochin Hospital
Barrett's esophagus (BE) is the major risk factor for esophageal adenocarcinoma (EAC). Systemic sclerosis (SSc) is associated with an increased risk of BE related to chronic reflux.
To determine the outcomes of BE and estimate the EAC risk in SSc patients over a 3-year prospective study.
SSc patients were recruited through EUSTAR network centers. Inclusion criterion was a recent histological finding of BE. The patients were then prospectively followed and, as recommended, a second esophageal endoscopy was performed according to the presence at baseline of BE-related dysplasia.
50 SSc patients with BE (40 without and 10 with dysplasia) were included and 46 completed the follow-up (138 patients-year). During the 3-year follow-up, 4/46 BE patients (3%/year) were diagnosed with high-grade dysplasia/EAC, of which one developed cardial EAC. EAC incidence in the BE sub-group with dysplasia increased to 4%/year compared to the absence of EAC case in the BE sub-group without dysplasia at baseline.
Our results, in accordance with previous published data suggesting an increased risk of esophageal or cardial adenocarcinoma in SSc, highlight the need for accurate follow-up of BE SSc patients at risk of developing adenocarcinoma.
To cite this abstract, please use the following information:
Wipff, Julien, Coriat, Romain, Masciocchi, Michela, Caramaschi, Paola, Derk, Chris T., Hachulla, Eric, et al; Outcomes of Barrett's Esophagus Related to Systemic Sclerosis: A 3-Year EULAR/EUSTAR Prospective Follow-Up Study. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :580